activity Synthesize Nanoparticles
activity Characterize Nanoparticles
activity Modify Surface
activity Prepare Samples
activity Conduct Toxicity Tests
activity Perform Stability Tests
activity Optimize Formulation
activity Scale Up Production
activity Conduct Clinical Trials
activity Analyze Results
activity File Patents
activity Publish Research
activity Attend Conferences
activity Collaborate with Researchers
activity Market Products
bind Synthesize Nanoparticles: Sample ID, Sample Type
bind Characterize Nanoparticles: Sample ID, Particle Size
bind Modify Surface: Sample ID, Sample Type
bind Prepare Samples: Sample ID
bind Conduct Toxicity Tests: Sample ID, Toxicity Level
bind Perform Stability Tests: Sample ID, Stability Duration
bind Optimize Formulation: Sample ID, Particle Size
bind Scale Up Production: Batch Number
bind Conduct Clinical Trials: Sample ID, Dosage
bind Analyze Results: Sample ID, Research Outcome
bind File Patents: Batch Number
bind Publish Research: Sample ID
bind Attend Conferences: Conference Name
bind Collaborate with Researchers: Research Outcome
bind Market Products: Market Region
Sample ID: integer between 1 and 999999
Sample Type: Quantum Dots, Metal Nanoparticles, Polymeric Nanoparticles
Particle Size: float between 1 and 1000
Toxicity Level: Low, Medium, High
Batch Number: integer between 1 and 10000
Stability Duration: float between 1 and 100
Dosage: float between 0.1 and 100
Research Outcome: Success, Partial Success, Failure
Conference Name: NanoTech Summit, International Nanotech Conference, Advanced Nanomaterials Conference
Market Region: North America, Europe, Asia
Init[Synthesize Nanoparticles] | |
Precedence[Synthesize Nanoparticles, Characterize Nanoparticles] | | |
Alternate Response[Modify Surface, Prepare Samples] | | |
Absence3[Conduct Toxicity Tests] | |
Chain Response[Synthesize Nanoparticles, Perform Stability Tests] | | |
Response[Perform Stability Tests, Optimize Formulation] | | |0,48,h
End[Scale Up Production] | |
Succession[Optimize Formulation, Conduct Clinical Trials] | | |
Alternate Response[Conduct Clinical Trials, Analyze Results] | | |0,30,d
Chain Response[Analyze Results, File Patents] | | |
Responded Existence[Analyze Results, Publish Research] | | |
Precedence[Attend Conferences, Publish Research] | | |
Chain Response[Attend Conferences, Collaborate with Researchers] | | |0,15,d
Alternate Succession[Collaborate with Researchers, Market Products] | | |0,60,d
Exactly[Market Products] | |